A panel created in the state of Oregon under the psilocybin legalization measure that was approved by voters last year has submitted a report stating that psilocybin possesses significant medical benefits for various health conditions. The Oregon Psilocybin Advisory Board subcommittee reviewed nearly 600 studies on psilocybin and came to the conclusion that the psychedelic had demonstrated effectiveness in decreasing anxiety and depression, even in fatal conditions.
The panel asserted that all the studies they reviewed used a clinically supervised setting. Their report, which was compiled after eight weeks of review, stated that psilocybin was found to increase spiritual well-being across studies, with the majority of the study participants rating their experiences with psilocybin as meaningful.
The psilocybin advisory board members — all 17 of them — were appointed in March of this year by Gov. Kate Brown. The objective of the board is to assist in the implementation of the aforementioned psychedelic reform measure.
Below is a list of some of the recommendations made by the panel for psilocybin implementation.
- The Oregon Health Authority should consider the risk of bias and strength of evidence when developing a psilocybin treatment framework.
- The Oregon Health Authority should collect more information from institutions, communities and people that haven’t been included in scientific literature, in order to stop evidence inequity.
- The state’s health authority should implement ways to ensure that psilocybin consumers and providers of these services are informed of the possible negative effects the substance can induce, after or during the administration of psilocybin.
- The Oregon Health Authority should look into the practicability of creating a voluntary process for monitoring the implementation of psilocybin services in the state.
- The state’s health authority should look into expanding the research on growing mushrooms that contain psilocybin, as they develop a regulatory framework.
- The OHA should also encourage the utilization of grain-based substrates for psilocybin mushroom cultivation instead of wood or dung and work to prioritize Psilocybe cubensis growing.
The state of Oregon is one of many states in the country looking into psychedelic reform as interest in this particular matter grows at the local, state and even federal level. Last week, legislators in Massachusetts listened to testimony concerning legislation designed to establish a panel that would study the consequences of legalizing various psychedelics, including ayahuasca and psilocybin.
Massachusetts cities of Cambridge, Somerville and Northampton have also passed measures that deprioritize the enforcement of laws against the distribution, use and possession of various psychedelics.
The fact that the Oregon Review Board reached its conclusion shows that several companies, including Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), appear more likely to succeed in their attempts to develop psychedelic-based medicines targeting several neurological conditions.
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.